Global Renal Denervation Treatment Market
Global Renal Denervation Treatment Market

Renal Denervation Treatment Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers, Others), Technology (Ultrasound, Radiofrequency, Ultrasound, Micro-infusion), Diseases (Hypertension, Kidney Diseases) Players and Region - Global Market Outlook to 2025

Renal Denervation Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Aug 2020 Edition 232 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Renal denervation is a minimally invasive endovascular catheter-based procedure to treat resistant hypertension. Renal denervation treatment is used for hypertension and chronic kidney disease. It uses radiofrequency waves to disrupt the overactive sympathetic nerves running along the arteries in the kidneys. The factors such as Increased Prevalence of Hypertension and Kidney Diseases among People, Increased Number of Diagnostic Centres and Hospitals and Changing Lifestyle of the People are the driving factors for the global renal denervation treatment market.

The market study is being classified, by Application (Hospitals, Ambulatory Surgical Centers and Others) and major geographies with country level break-up.

St. Jude Medical (United States), ReCor Medical, Inc. (United States), Boston Scientific (United States), Medtronic (Ireland), Kona Medical, Inc. (United States), Mercator MedSystems, Inc. (United States), Terumo Corporation (Japan), Abbott Laboratories (United States), Theragenics Corporation (United States) and Hansen Medical, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Biosense Webster Inc (United States) and Ablative Solutions, Inc. (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Renal Denervation Treatment market by Type, Application and Region.

On the basis of geography, the market of Renal Denervation Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Hypertension and Kidney Diseases among People
  • Increased Number of Diagnostic Centres and Hospitals
  • Changing Lifestyle of the People

Market Trend
  • Growth in the Healthcare Infrastructure in Developing Countries
  • Cost-Effectiveness of the Procedure

Restraints
  • Risks Associated with the Procedure
  • Less Awareness among People About Treatment

Opportunities
  • Growing in the Healthcare Industry Worldwide
  • Increased Research and Development Activities

Challenges
  • Stringent Government Rules and Regulations


In November 2019, Terumo Corporation has announced that it has decided to acquire Aortica Corporation, a United States based company dedicated to advancing the science of personalized vascular therapy.


Key Target Audience
Renal Denervation Treatment Providers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
By Technology
  • Ultrasound
  • Radiofrequency
  • Ultrasound
  • Micro-infusion

By Diseases
  • Hypertension
  • Kidney Diseases

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Hypertension and Kidney Diseases among People
      • 3.2.2. Increased Number of Diagnostic Centres and Hospitals
      • 3.2.3. Changing Lifestyle of the People
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Growth in the Healthcare Infrastructure in Developing Countries
      • 3.4.2. Cost-Effectiveness of the Procedure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Renal Denervation Treatment, by Application, Technology, Diseases and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Renal Denervation Treatment (Value)
      • 5.2.1. Global Renal Denervation Treatment by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Ambulatory Surgical Centers
        • 5.2.1.3. Others
      • 5.2.2. Global Renal Denervation Treatment by: Technology (Value)
        • 5.2.2.1. Ultrasound
        • 5.2.2.2. Radiofrequency
        • 5.2.2.3. Ultrasound
        • 5.2.2.4. Micro-infusion
      • 5.2.3. Global Renal Denervation Treatment by: Diseases (Value)
        • 5.2.3.1. Hypertension
        • 5.2.3.2. Kidney Diseases
      • 5.2.4. Global Renal Denervation Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Renal Denervation Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. St. Jude Medical (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ReCor Medical, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boston Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kona Medical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mercator MedSystems, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Terumo Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Theragenics Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hansen Medical, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Renal Denervation Treatment Sale, by Application, Technology, Diseases and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Renal Denervation Treatment (Value)
      • 7.2.1. Global Renal Denervation Treatment by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Ambulatory Surgical Centers
        • 7.2.1.3. Others
      • 7.2.2. Global Renal Denervation Treatment by: Technology (Value)
        • 7.2.2.1. Ultrasound
        • 7.2.2.2. Radiofrequency
        • 7.2.2.3. Ultrasound
        • 7.2.2.4. Micro-infusion
      • 7.2.3. Global Renal Denervation Treatment by: Diseases (Value)
        • 7.2.3.1. Hypertension
        • 7.2.3.2. Kidney Diseases
      • 7.2.4. Global Renal Denervation Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Renal Denervation Treatment: by Application(USD Million)
  • Table 2. Renal Denervation Treatment Hospitals , by Region USD Million (2014-2019)
  • Table 3. Renal Denervation Treatment Ambulatory Surgical Centers , by Region USD Million (2014-2019)
  • Table 4. Renal Denervation Treatment Others , by Region USD Million (2014-2019)
  • Table 5. Renal Denervation Treatment: by Technology(USD Million)
  • Table 6. Renal Denervation Treatment Ultrasound , by Region USD Million (2014-2019)
  • Table 7. Renal Denervation Treatment Radiofrequency , by Region USD Million (2014-2019)
  • Table 8. Renal Denervation Treatment Ultrasound , by Region USD Million (2014-2019)
  • Table 9. Renal Denervation Treatment Micro-infusion , by Region USD Million (2014-2019)
  • Table 10. Renal Denervation Treatment: by Diseases(USD Million)
  • Table 11. Renal Denervation Treatment Hypertension , by Region USD Million (2014-2019)
  • Table 12. Renal Denervation Treatment Kidney Diseases , by Region USD Million (2014-2019)
  • Table 13. South America Renal Denervation Treatment, by Country USD Million (2014-2019)
  • Table 14. South America Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 15. South America Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 16. South America Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 17. Brazil Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 18. Brazil Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 19. Brazil Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 20. Argentina Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 21. Argentina Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 22. Argentina Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 23. Rest of South America Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 24. Rest of South America Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 25. Rest of South America Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 26. Asia Pacific Renal Denervation Treatment, by Country USD Million (2014-2019)
  • Table 27. Asia Pacific Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 28. Asia Pacific Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 29. Asia Pacific Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 30. China Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 31. China Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 32. China Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 33. Japan Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 34. Japan Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 35. Japan Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 36. India Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 37. India Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 38. India Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 39. South Korea Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 40. South Korea Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 41. South Korea Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 42. Taiwan Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 43. Taiwan Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 44. Taiwan Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 45. Australia Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 46. Australia Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 47. Australia Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 48. Rest of Asia-Pacific Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 51. Europe Renal Denervation Treatment, by Country USD Million (2014-2019)
  • Table 52. Europe Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 53. Europe Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 54. Europe Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 55. Germany Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 56. Germany Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 57. Germany Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 58. France Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 59. France Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 60. France Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 61. Italy Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 62. Italy Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 63. Italy Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 64. United Kingdom Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 65. United Kingdom Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 66. United Kingdom Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 67. Netherlands Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 68. Netherlands Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 69. Netherlands Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 70. Rest of Europe Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 71. Rest of Europe Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 72. Rest of Europe Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 73. MEA Renal Denervation Treatment, by Country USD Million (2014-2019)
  • Table 74. MEA Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 75. MEA Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 76. MEA Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 77. Middle East Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 78. Middle East Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 79. Middle East Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 80. Africa Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 81. Africa Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 82. Africa Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 83. North America Renal Denervation Treatment, by Country USD Million (2014-2019)
  • Table 84. North America Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 85. North America Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 86. North America Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 87. United States Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 88. United States Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 89. United States Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 90. Canada Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 91. Canada Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 92. Canada Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 93. Mexico Renal Denervation Treatment, by Application USD Million (2014-2019)
  • Table 94. Mexico Renal Denervation Treatment, by Technology USD Million (2014-2019)
  • Table 95. Mexico Renal Denervation Treatment, by Diseases USD Million (2014-2019)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Renal Denervation Treatment: by Application(USD Million)
  • Table 107. Renal Denervation Treatment Hospitals , by Region USD Million (2020-2025)
  • Table 108. Renal Denervation Treatment Ambulatory Surgical Centers , by Region USD Million (2020-2025)
  • Table 109. Renal Denervation Treatment Others , by Region USD Million (2020-2025)
  • Table 110. Renal Denervation Treatment: by Technology(USD Million)
  • Table 111. Renal Denervation Treatment Ultrasound , by Region USD Million (2020-2025)
  • Table 112. Renal Denervation Treatment Radiofrequency , by Region USD Million (2020-2025)
  • Table 113. Renal Denervation Treatment Ultrasound , by Region USD Million (2020-2025)
  • Table 114. Renal Denervation Treatment Micro-infusion , by Region USD Million (2020-2025)
  • Table 115. Renal Denervation Treatment: by Diseases(USD Million)
  • Table 116. Renal Denervation Treatment Hypertension , by Region USD Million (2020-2025)
  • Table 117. Renal Denervation Treatment Kidney Diseases , by Region USD Million (2020-2025)
  • Table 118. South America Renal Denervation Treatment, by Country USD Million (2020-2025)
  • Table 119. South America Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 120. South America Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 121. South America Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 122. Brazil Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 123. Brazil Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 124. Brazil Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 125. Argentina Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 126. Argentina Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 127. Argentina Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 128. Rest of South America Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 129. Rest of South America Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 130. Rest of South America Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 131. Asia Pacific Renal Denervation Treatment, by Country USD Million (2020-2025)
  • Table 132. Asia Pacific Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 133. Asia Pacific Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 134. Asia Pacific Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 135. China Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 136. China Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 137. China Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 138. Japan Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 139. Japan Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 140. Japan Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 141. India Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 142. India Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 143. India Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 144. South Korea Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 145. South Korea Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 146. South Korea Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 147. Taiwan Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 148. Taiwan Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 149. Taiwan Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 150. Australia Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 151. Australia Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 152. Australia Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 153. Rest of Asia-Pacific Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 154. Rest of Asia-Pacific Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 155. Rest of Asia-Pacific Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 156. Europe Renal Denervation Treatment, by Country USD Million (2020-2025)
  • Table 157. Europe Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 158. Europe Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 159. Europe Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 160. Germany Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 161. Germany Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 162. Germany Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 163. France Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 164. France Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 165. France Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 166. Italy Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 167. Italy Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 168. Italy Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 169. United Kingdom Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 170. United Kingdom Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 171. United Kingdom Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 172. Netherlands Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 173. Netherlands Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 174. Netherlands Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 175. Rest of Europe Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 176. Rest of Europe Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 177. Rest of Europe Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 178. MEA Renal Denervation Treatment, by Country USD Million (2020-2025)
  • Table 179. MEA Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 180. MEA Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 181. MEA Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 182. Middle East Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 183. Middle East Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 184. Middle East Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 185. Africa Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 186. Africa Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 187. Africa Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 188. North America Renal Denervation Treatment, by Country USD Million (2020-2025)
  • Table 189. North America Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 190. North America Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 191. North America Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 192. United States Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 193. United States Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 194. United States Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 195. Canada Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 196. Canada Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 197. Canada Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 198. Mexico Renal Denervation Treatment, by Application USD Million (2020-2025)
  • Table 199. Mexico Renal Denervation Treatment, by Technology USD Million (2020-2025)
  • Table 200. Mexico Renal Denervation Treatment, by Diseases USD Million (2020-2025)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Renal Denervation Treatment: by Application USD Million (2014-2019)
  • Figure 5. Global Renal Denervation Treatment: by Technology USD Million (2014-2019)
  • Figure 6. Global Renal Denervation Treatment: by Diseases USD Million (2014-2019)
  • Figure 7. South America Renal Denervation Treatment Share (%), by Country
  • Figure 8. Asia Pacific Renal Denervation Treatment Share (%), by Country
  • Figure 9. Europe Renal Denervation Treatment Share (%), by Country
  • Figure 10. MEA Renal Denervation Treatment Share (%), by Country
  • Figure 11. North America Renal Denervation Treatment Share (%), by Country
  • Figure 12. Global Renal Denervation Treatment share by Players 2019 (%)
  • Figure 13. Global Renal Denervation Treatment share by Players (Top 3) 2019(%)
  • Figure 14. Global Renal Denervation Treatment share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. St. Jude Medical (United States) Revenue, Net Income and Gross profit
  • Figure 17. St. Jude Medical (United States) Revenue: by Geography 2019
  • Figure 18. ReCor Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. ReCor Medical, Inc. (United States) Revenue: by Geography 2019
  • Figure 20. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 21. Boston Scientific (United States) Revenue: by Geography 2019
  • Figure 22. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Medtronic (Ireland) Revenue: by Geography 2019
  • Figure 24. Kona Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Kona Medical, Inc. (United States) Revenue: by Geography 2019
  • Figure 26. Mercator MedSystems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mercator MedSystems, Inc. (United States) Revenue: by Geography 2019
  • Figure 28. Terumo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Terumo Corporation (Japan) Revenue: by Geography 2019
  • Figure 30. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 31. Abbott Laboratories (United States) Revenue: by Geography 2019
  • Figure 32. Theragenics Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 33. Theragenics Corporation (United States) Revenue: by Geography 2019
  • Figure 34. Hansen Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Hansen Medical, Inc. (United States) Revenue: by Geography 2019
  • Figure 36. Global Renal Denervation Treatment: by Application USD Million (2020-2025)
  • Figure 37. Global Renal Denervation Treatment: by Technology USD Million (2020-2025)
  • Figure 38. Global Renal Denervation Treatment: by Diseases USD Million (2020-2025)
  • Figure 39. South America Renal Denervation Treatment Share (%), by Country
  • Figure 40. Asia Pacific Renal Denervation Treatment Share (%), by Country
  • Figure 41. Europe Renal Denervation Treatment Share (%), by Country
  • Figure 42. MEA Renal Denervation Treatment Share (%), by Country
  • Figure 43. North America Renal Denervation Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • St. Jude Medical (United States)
  • ReCor Medical, Inc. (United States)
  • Boston Scientific (United States)
  • Medtronic (Ireland)
  • Kona Medical, Inc. (United States)
  • Mercator MedSystems, Inc. (United States)
  • Terumo Corporation (Japan)
  • Abbott Laboratories (United States)
  • Theragenics Corporation (United States)
  • Hansen Medical, Inc. (United States)
Additional players considered in the study are as follows:
Biosense Webster Inc (United States) , Ablative Solutions, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation